A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis

Spine (Phila Pa 1976). 2004 Sep 1;29(17):1885-92. doi: 10.1097/01.brs.0000137062.79201.98.

Abstract

Study design: A prospective, randomized, controlled, multicenter clinical study was conducted.

Objective: To compare the clinical and radiographic outcomes of patients treated with OP-1 (BMP-7) Putty to autogenous iliac crest bone graft for one-level uninstrumented posterolateral fusion of the lumbar spine following decompressive laminectomy for the treatment of symptomatic degenerative spondylolisthesis with spinal stenosis.

Background: Preclinical studies have demonstrated that osteoinductive recombinant human osteogenic protein 1 in the form of OP-1 Putty is successful at achieving a posterolateral fusion in rabbits and dogs without any significant safety concerns.

Methods: Thirty-six patients with degenerative lumbar spondylolisthesis and symptoms of neurogenic claudication were randomized (2:1) to either OP-1 Putty (3.5 mg of OP-1 per side) or autogenous iliac crest bone graft for one-level uninstrumented posterolateral fusion following a decompressive laminectomy. Enrollment in the study was complete when 24 OP-1 Putty patients and 12 autograft patients had been randomized and treated. A patient administered Oswestry scale and SF-36 scale were used to determine clinical outcomes. Independent, blinded neuroradiologists reviewed both static and dynamic radiographs to determine fusion status.

Results: At the 1-year follow-up, 32 patients were available for clinical analysis and 29 patients were available for radiographic review. Clinical success as measured on the Oswestry scale was achieved by 18 of 21 (86%) OP-1 Putty patients and 8 of 11 (73%) autograft patients. SF-36 pain index scores showed similar results. Fourteen of 19 (74%) OP-1 Putty patients and 6 of 10 (60%) autograft patients achieved a successful posterolateral fusion fulfilling all fusion criteria. Of the 29 evaluable patients, 15 were both clinical and radiographic successes, 5 were radiographic successes but were clinical failures, 1 patient was both a radiographic and clinical failure, and 8 patients were radiographic failures but were clinical successes. No systemic toxicity, ectopic bone formation, recurrent stenosis, or other adverse events related to the OP-1 Putty implant were observed.

Conclusion: Although the posterolateral spine is a challenging fusion environment in patients with degenerative spondylolisthesis, successful radiographic fusion was obtained using OP-1 Putty at a rate that was similar to autograft given the number of patients in this study. Importantly, there were no apparent adverse consequences related to the use of the OP-1 Putty implant in this patient population.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biocompatible Materials
  • Bone Morphogenetic Protein 7
  • Bone Morphogenetic Proteins / administration & dosage
  • Bone Morphogenetic Proteins / therapeutic use*
  • Bone Substitutes / administration & dosage
  • Bone Substitutes / therapeutic use*
  • Bone Transplantation
  • Carboxymethylcellulose Sodium / administration & dosage
  • Carboxymethylcellulose Sodium / therapeutic use
  • Collagen Type I / administration & dosage
  • Collagen Type I / therapeutic use
  • Decompression, Surgical
  • Female
  • Follow-Up Studies
  • Humans
  • Laminectomy
  • Lumbar Vertebrae / surgery*
  • Male
  • Materials Testing
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Radiography
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Single-Blind Method
  • Spinal Fusion / methods*
  • Spinal Stenosis / diagnostic imaging
  • Spinal Stenosis / etiology
  • Spinal Stenosis / surgery*
  • Spondylolisthesis / complications
  • Spondylolisthesis / diagnostic imaging
  • Spondylolisthesis / surgery*
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • BMP7 protein, human
  • Biocompatible Materials
  • Bone Morphogenetic Protein 7
  • Bone Morphogenetic Proteins
  • Bone Substitutes
  • Collagen Type I
  • Recombinant Proteins
  • Carboxymethylcellulose Sodium